Sophie Vantyghem

Successful treatment of acute promyelocytic leukemia with arsenic trioxide and all-trans retinoic acid in a double lung and kidney transplanted patient

P. Chevallier, M. Béné, P. Moreau, 2016, Annals of Hematology.

Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide

P. Chevallier, M. Béné, P. Moreau, 2020, Acta oncologica.

Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience

P. Chevallier, P. Moreau, C. Touzeau, 2020, Bone Marrow Transplantation.

Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant

P. Chevallier, M. Béné, P. Moreau, 2021, British journal of haematology.

B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

P. Chevallier, M. Rimbert, M. Béné, 2022, Transplantation and Cellular Therapy.

Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study

Elsa, P. Chevallier, M. Béné, 2021 .

Diagnosis and prognosis are comforted by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.

P. Chevallier, M. Béné, P. Moreau, 2020, Haematologica.

Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.

P. Chevallier, C. Touzeau, B. Mahé, 2024, American journal of hematology.